2020 American Transplant Congress
National Trends in Locoregional Therapy among Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) in the United States
1Stanford University, Redwood City, CA, 2University of California, San Francisco, San Francisco, CA
*Purpose: Advances in locoregional therapy (LRT) have expanded treatment options for patients with HCC. As recent policy changes in the United States (US) have lengthened…2020 American Transplant Congress
Does Choice of Inferior Vena Cava Reconstruction Technique Have an Impact on the Short and Long Term Postoperative Renal Function in Liver Transplant Recipient?
1Vancouver General Hospital, Vancouver, BC, Canada, 2Baylor University Medical Center, Dallas, TX
*Purpose: Postoperative acute kidney injury (AKI) is common after liver transplant (Oltx). It is associated with increased morbidity and mortality and is a risk factor…2020 American Transplant Congress
Assessing Immunosuppression with Immunological Testing and Surveillance Biopsies Late after Liver and Intestine Transplantation (LT, IT)
Pediatric Transplant, Pittsburgh, PA
*Purpose: Assessing adequacy of immunosuppression is essential during late allograft surveillance after LT or IT.*Methods: To explain why allograft function tests can be normal despite…2020 American Transplant Congress
Liver Transplant with Donation after Cardiac Death versus Donation after Brain Death Donors: Survival and Outcomes at 10 Years
1Surgery, Beth Israel Deaconess Medical Center, Boston, MA, 2Harvard Medical School, Boston, MA
*Purpose: This observational study utilizes the SRTR database to assess liver transplant outcomes after Donation after Cardiac Death (DCD) versus Donation after Brain Death (DBD)…2020 American Transplant Congress
CEACAM1 / ASK1 / p38 Signaling Axis Alleviates Peri-Transplant Liver Injury: From Mouse-to-Human
1UCLA, Los Angeles, CA, 2Kyoto University, Kyoto, Japan
*Purpose: Although CEACAM1 (CM1; carcinoembryonic antigen-related cell adhesion molecule 1; CD66a) regulates hepatic metabolic homeostasis, its role in orthotopic liver transplantation (OLT) remains unknown. A…2020 American Transplant Congress
Induction Immunosuppression with Thymoglobulin May Improve Graft Outcomes without Increasing a Risk for Infection in Patients Undergoing Liver Transplantation Alone
*Purpose: Immunosuppression protocols for liver transplant (LT) vary between institutions and roles of induction immunosuppression in LT remain controversial. The aim of this study was…2020 American Transplant Congress
Development of Novel Multivariable Logistic Regression Model for Predicting Graft Failure within 2 Weeks and 4 Weeks after Liver Transplantation Using Post-Transplantation Laboratory Values
Transplantation, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: This study designed a prediction model for graft failure after liver transplantation.*Methods: Multivariable logistic regression including aspartate aminotransferase (AST), total bilirubin (TB), and international…2020 American Transplant Congress
Development of Recommendations for Liver Transplant Anesthesia Teams Using a Modified Delphi Process
Department of Anesthesiology, University of Colorado, Aurora, CO
*Purpose: We utilized a modified Delphi technique to develop recommendations to guide service responsibilities for liver transplant anesthesia teams (LTATs).*Methods: The Society for the Advancement…2020 American Transplant Congress
The Link between Waitlist Mortality and Access to Transplant, an Imaginative Reality
*Purpose: Liver transplant waitlist mortality due to inadequate access to livers is the Achilles heel in liver transplantation in United States. This remains amongst the…2020 American Transplant Congress
The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma
1Department of Medicine, UCSF, San Francisco, CA, 2Department of Medicine, USC, Los Angeles, CA
*Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to 100 but
- « Previous Page
- 1
- …
- 44
- 45
- 46
- 47
- 48
- …
- 180
- Next Page »